Omvoh (mirikizumab-mrkz) for moderately to severely active Crohn’s disease in adults. Omvoh is now approved in the U.S. for ...

The study's primary goal is to assess the therapy’s tolerability, pharmacokinetics and safety in healthy volunteers.

Inflammatory Bowel Disease (IBD) is a term for chronic inflammatory conditions affecting the digestive tract, primarily Crohn ...

Ulcerative colitis during pregnancy is manageable However timely detection and proper treatment are crucial to ensure a ...

Company on track to report topline data in first half of 2025 Positive preliminary data from all five single ascending dose (SAD) cohorts ranging from 15mg to 450mg support safety and tolerability of ...

(RTTNews) - Palisade Bio, Inc. (PALI), Thursday announced a preliminary data from five planned Single Ascending Dose cohorts, showing that PALI-2018 was well-tolerated among doses ranging from 15 mg ...

Children who were diagnosed with inflammatory bowel disease (IBD) showed a decline in height, weight, and body mass index ...

Accepted by the Scottish Medicines Consortium for Adults with Moderately to Severely Active Ulcerative ColitisPRESS RELEASE – For UK consumer health, medical and trade media onlyRisankizumab will be ...

The U.S. Food and Drug Administration has approved Eli Lilly's Omvoh (mirikizumab-mrkz) for the treatment of moderately to ...

Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting ...

Researchers report the ability of tofacitinib to reduce infection risk with SARS-CoV-2 in individuals who are deficient in ...